Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Abstract | BACKGROUND: PATIENTS AND METHODS: Patients who had undergone ≤ 1 previous chemotherapy regimen for measurable ER(-) and PR(-) MBC received saracatinib 175 mg orally daily. The primary endpoint was disease control defined as complete response (CR) + partial response (PR) + stable disease (SD) > 6 months. Secondary endpoints included toxicity and progression-free survival (PFS). Levels of circulating tumor cells (CTCs) in response to therapy were measured over time. RESULTS: CONCLUSIONS: These efficacy results were not sufficiently promising to justify continued accrual to this study. Based on this series, saracatinib does not appear to have significant single-agent activity for the treatment of patients with ER(-)/PR(-) MBC.
|
Authors | Ayca Gucalp, Joseph A Sparano, James Caravelli, Jean Santamauro, Sujata Patil, Alyson Abbruzzi, Christine Pellegrino, Jackie Bromberg, Chau Dang, Maria Theodoulou, Joan Massague, Larry Norton, Clifford Hudis, Tiffany A Traina |
Journal | Clinical breast cancer
(Clin Breast Cancer)
Vol. 11
Issue 5
Pg. 306-11
(Oct 2011)
ISSN: 1938-0666 [Electronic] United States |
PMID | 21729667
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011. Published by Elsevier Inc. |
Chemical References |
- Antineoplastic Agents
- Benzodioxoles
- Protein Kinase Inhibitors
- Quinazolines
- Receptors, Estrogen
- Receptors, Progesterone
- saracatinib
- Protein-Tyrosine Kinases
|
Topics |
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Benzodioxoles
(administration & dosage, adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, metabolism, pathology)
- Disease-Free Survival
- Female
- Humans
- Middle Aged
- Neoplasm Metastasis
- New York City
- Protein Kinase Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Quinazolines
(administration & dosage, adverse effects, therapeutic use)
- Receptors, Estrogen
- Receptors, Progesterone
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|